---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-014858"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T10:41:53.066209+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Hepion shareholders reject reverse stock split amendment at 2025 annual meeting

## Summary
- Reverse stock split proposal (1:5 to 1:20) failed with 2.25M for, 3.70M against; not approved.
- All four director nominees (Brancaccio, Block, Lbiati, Purcell) elected despite majority of votes withheld.
- Ratification of Grassi & Co. as auditors passed with 4.76M for vs 1.17M against.
- Advisory say-on-pay failed with 162K for, 337K against.
- Only 10.9M shares outstanding; broker non-votes totaled 5.46M on most proposals.

## SEC filing metadata
- accession: 0001641172-25-014858
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000164117225014858/0001641172-25-014858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000164117225014858/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-014858
- JSON: https://secwatch.observer/filing/0001641172-25-014858.json
- Plain text: https://secwatch.observer/filing/0001641172-25-014858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.